

FOR IMMEDIATE RELEASE:

MAKO Surgical Corp. Closes \$20 Million In Series B Funding

HOLLYWOOD, Fla. (August 8, 2005) – MAKO Surgical Corp., an emerging medical technology company targeting the \$4 billion and rapidly growing knee replacement medical device sector, announced today that it has closed on a \$20 million Series B round of private equity financing. Participants in the financing round included funds to which MDS Capital provides services, The Exxel Group, Aperture Venture Partners, MediTech Advisors, Ivy Capital Partners, Sycamore Ventures and existing MAKO investors. MAKO's proprietary solution, called Makoplasty™, targets early stage knee therapies and goes beyond traditional minimally invasive procedures to enable rapid patient recovery and improved anatomical functionality. MAKO's revolutionary technology enables a surgeon to digitally sculpt and preserve bone tissue through small portals in a highly reproducible and simple manner.

“We are excited to welcome such a high caliber group of investors with extensive experience in the healthcare sector to the MAKO team,” said MAKO's President and CEO, Dr. Maurice R. Ferré. “Given the significant increase in aging population, active life style patients who are looking for alternative solutions to a long hospital stay and a long rehabilitation period will significantly benefit from Makoplasty™.”

MAKO plans to use the proceeds to complete the development of its products and establish its initial clinical sites. MAKO's proprietary technology platform has already been granted marketing clearance by the FDA through the 510(k) Premarket Notification process.

“We are pleased to support MAKO as it continues to develop unique solutions for the knee replacement market,” said Dr. Anthony J. Natale, Venture Partner at lead investor MDS Capital. “MAKO's technology, synthesizing advances in orthopedic implant design and surgical robotics, will enable a significant step forward in the movement towards less and minimally invasive orthopedic surgical procedures, resulting in improved patient outcomes and quality of life.” Dr. Natale also stated “MAKO's current financing is the largest medical technology venture transaction in the State of Florida this year and we are happy to support the continuing expansion of the healthcare and life sciences industry in the State.”

About MAKO Surgical Corporation

MAKO Surgical Corp., located in Hollywood, Florida, is a privately-held emerging orthopaedic company that is developing advanced technologies and procedures for the rapidly growing minimally invasive total joint market. MAKO is targeting the \$4 billion worldwide knee surgery market with proprietary technology that will enable truly minimally invasive partial and total knee replacement surgery. MAKO's proprietary Makoplasty™ provides a novel solution that will enable rapid patient recovery and improved anatomical functionality. For more information, please contact the company at info@makosurgical.com.

About MDS Capital Corp.

MDS Capital Corp. and affiliates, with approximately \$1 billion under management, is a leading North American venture capital company focused exclusively on providing financial support and other services to help build emerging life science companies. The company provides a continuum of capital, from early through later stages, by raising capital in public and private institutional funds. Additional information about MDS Capital Corp. is available at <http://www.mdscapital.com>.

MDS Capital Corp. operates in a strategic relationship with MDS Inc. The company provides a diverse range of superior products and services to increase their customers' speed, precision and productivity in the drug development and disease diagnosis processes. Find out more at <http://www.mdsintl.com>.

###